SMAC: Clinical Complexity in Internal Medicine Wards. San MAtteo Complexity Study

Sponsor
IRCCS Policlinico S. Matteo (Other)
Overall Status
Recruiting
CT.gov ID
NCT03439410
Collaborator
(none)
2,000
1
60
33.3

Study Details

Study Description

Brief Summary

The progressive rising of multimorbidity, which has been always considered the hallmark of clinical complexity (CC), has made management of the "complex" patient one of the most topical and challenging issues in medicine. However, patient-related factors (multimorbidity, age, frailty, disease severity) pertain only to the biological complexity, while CC is the result of the dynamic interaction between biological complexity and a number of other coexisting factors (socio-economic, cultural, behavioural, environmental). Starting from these premises, the investigators designed a five-year observational prospective longitudinal study that aims to validate and compare a CC score system on a large cohort of patients (n=1000) admitted in internal medicine wards. Clinicians, biostatisticians and epidemiologists will cooperate into the project. A questionnaire that encompasses the main biological and extra-biological factors was designed (Clinical Complexity Index, CCI) by a multiprofessional consensus. This questionnaire will be administered by the investigators to the patients and validated. Consecutive patients will be enrolled every other week for two years and followed-up for 5 years. The primary endpoint will be the validation of the CCI. Thereafter, the investigators will evaluate the correlation between the CCI and the length of stay of the index hospitalization, assuming that a higher CCI score is associated with longer length of stay. The secondary endpoints will be the demonstration of the association between higher CCI score and more health resources utilization (i.e., evaluating occurrence of hospital readmissions, number of accesses to the emergency room, visits at the outpatient clinic, different drugs prescribed and hospital reimbursement according to the local diagnosis-related group [DRG] system) along with worse prognosis (mortality at 1 and 5 years).

Condition or Disease Intervention/Treatment Phase
  • Other: Clinical Complexity Index

Detailed Description

The Clinical Complexity Index (CCI) that will be validated is made of 25 different variables, divided into 5 domains (biological, socioeconomic, behavioral, environmental, cultural). All variables were dichotomised and were coded -1 (absence of the variable) and +1 (presence of the variable). For each variable, the answer "yes" increases the degree of complexity. See Citations for further details.

Here is the CCI that will be used in the study:

BIOLOGICAL DOMAIN Age > 75 years yes☐ +1 no☐ -1 Intake ≥ 5 medications yes☐ +1 no☐ -1 Cumulative Illness Rating Scale (CIRS) > 3 and/or CIRS severity >3 yes☐ +1 no☐ -1 ↑ frailty (Edmonton Frail Scale > 5) yes☐ +1 no☐ -1

↓ mobilization (Barthel<60) yes☐ +1 no☐ -1

SOCIO-ECONOMIC DOMAIN Living alone yes☐ +1 no☐ -1 Income < 1000 €/month yes☐ +1 no☐ -1 Unemployment/precarious work yes☐ +1 no☐ -1 Dependent/disabled family member yes☐ +1 no☐ -1 Need for a caregiver yes☐ +1 no☐ -1

BEHAVIOURAL DOMAIN Inadequate adherence to medications yes☐ +1 no☐ -1 Active smoking of at least 4 cigarettes/day yes☐ +1 no☐ -1 Alcohol (>3 Alcohol Units/day) and/or drug abuse yes☐ +1 no☐ -1 Inappropriate diet yes☐ +1 no☐ -1 Cognitive impairment (Short Blessed Test > 9) yes☐ +1 no☐ -1

ENVIRONMENTAL DOMAIN Institutionalization yes☐ +1 no☐ -1 Difficult access to healthcare yes☐ +1 no☐ -1 Presence of home architectural barriers yes☐ +1 no☐ -1 Occupational exposure to toxins yes☐ +1 no☐ -1 Air pollution yes☐ +1 no☐ -1

CULTURAL DOMAIN Schooling < 8 years yes☐ +1 no☐ -1 Insufficient access to information yes☐ +1 no☐ -1 Lack of adherence to health screening programs yes☐ +1 no☐ -1 Language barriers yes☐ +1 no☐ -1 Perceived discrimination yes☐ +1 no☐ -1

The investigators will administer the CCI to all patients admitted to the wards (Internal Medicine and Subacute ward), according the study protocol. All the enrolled patients will be followed-up with a phone call after after discharge (at 4-8-12 months) for collecting the following data: occurrence of hospital readmission within 1 month after discharge; the number of readmissions; the number of accesses to the emergency room (ER); the number of visits at the outpatient clinic; the number of different drugs prescribed; mortality. Mortality will also be assessed once a year for 5 years.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
2000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Development of a Mathematical Model of Clinical Complexity and of an Index for Its Practical Evaluation in Observational Prospective Longitudinal Studies. San MAtteo Complexity Study
Actual Study Start Date :
Nov 6, 2017
Anticipated Primary Completion Date :
Nov 6, 2019
Anticipated Study Completion Date :
Nov 6, 2022

Arms and Interventions

Arm Intervention/Treatment
Internal Medicine ward

The Clinical Complexity Index (CCI) will be administered to all patients admitted to the ward.

Other: Clinical Complexity Index
Clinical Complexity Index (CCI) will be administered at the time of admission to the ward.

Subacute ward

The Clinical Complexity Index (CCI) will be administered to all patients admitted to the ward.

Other: Clinical Complexity Index
Clinical Complexity Index (CCI) will be administered at the time of admission to the ward.

Outcome Measures

Primary Outcome Measures

  1. Validation of the Clinical Complexity Index (CCI) [2 years]

    Validation of the Clinical Complexity Index (CCI) proposed in the project (see first Citation and Study Description for further details). This index should measure patients' clinical complexity, including biological, socioeconomic, cultural, behavioral, and envirnomental domains. The total score range is -25 to +25 (-5 to +5 per each domain). The investigators expect that a higher value is associated with a worse outcome (higher clinical complexity).

Secondary Outcome Measures

  1. Length of stay [2 years]

    The investigators will measure the length of stay (unit of measurement: days) of each enrolled patient.

  2. Healthcare expenditure and utilization [1 year]

    To demonstrate the association of the Clinical Complexity Index (CCI) with the use of health resources, including the occurrence of hospital readmission within 1 month; the number of readmissions during the first 12 months; the number of accesses to the emergency room (ER) during the first 12 months; the number of visits at the outpatient clinic during the first 12 months; the number of different drugs prescribed during the first 12 months; the hospital reimbursement according to the Regional DRG system for the index hospitalization. Each of these items will be separately analyzed.

  3. Mortality [5 years]

    To evaluate the association between a higher Clinical Complexity Index (CCI) score and mortality at 1 and 5 years.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥ 18

  • Hospitalized in one of the participating Units (Internal Medicine wards or Subacute ward)

Exclusion Criteria:
  • Already enrolled in the study during a previous hospitalization

  • Denied informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fondazione IRCCS Policlinico San Matteo Pavia Lombardia Italy 27100

Sponsors and Collaborators

  • IRCCS Policlinico S. Matteo

Investigators

  • Principal Investigator: Gino R Corazza, MD, Fondazione IRCCS Policlinico San Matteo

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Gino Roberto Corazza, Full Professor of Internal Medicine, IRCCS Policlinico S. Matteo
ClinicalTrials.gov Identifier:
NCT03439410
Other Study ID Numbers:
  • SMAC Study
First Posted:
Feb 20, 2018
Last Update Posted:
Feb 26, 2019
Last Verified:
Feb 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Gino Roberto Corazza, Full Professor of Internal Medicine, IRCCS Policlinico S. Matteo

Study Results

No Results Posted as of Feb 26, 2019